Treatment with HBX 41,108 activates the transcription of p53 target genes without inducing genotoxic stress and p53-dependent apoptosis subsequently resulting in inhibiting tumor proliferation (Colland et al., 2009). The gene discussed is TP53; the disease is neoplasm.